Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Deals with Hims & Hers, LifeMD and Ro follow dismissal of a lawsuit that challenged the FDA's determination Wegovy is no ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...

Novo Nordisk has pulled ahead in the race to bring the first oral GLP-1 for obesity to market. The company announced Friday ...

CVS’ pharmacy benefit manager Caremark also reached an agreement with Danish drugmaker Novo Nordisk to give its weight loss drug Wegovy preferred access on Caremark’s standard formulary ...

Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... personalize the content you receive, or create and administer your account. Provide specific products and services to you ...

Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...